Table 1.
Clinical and Severity Characteristics of the 2 Study Groups (Immunocompetent vs Immunocompromised)
| Variable | Patients, No. (%)a | P Value | |
|---|---|---|---|
| Immunocompetent (n = 3050) | Immunocompromised (n = 652) |
||
| Age, median (IQR) | 69 (54–81) | 65 (52–74) | <.001 |
| Underweight | 125 (6.5) | 41 (10.5) | .004 |
| Malnutrition | 243 (8.0) | 80 (12.3) | <.001 |
| Bedridden | 355 (11.6) | 60 (9.2) | .04 |
| Chronic aspiration | 224 (7.3) | 33 (5.1) | .02 |
| Bronchiectasis | 136 (4.5) | 42 (6.4) | .03 |
| Severe COPD | 72 (2.4) | 28 (4.3) | .006 |
| Interstitial lung disease | 60 (2.0) | 35 (5.4) | <.001 |
| Lung transplantation | 0 (0.0) | 7 (1.1) | <.001 |
| Tracheostomy | 37 (1.2) | 16 (2.5) | .02 |
| Hypertension | 1401 (45.9) | 254 (39.0) | .001 |
| Liver disease | 103 (3.4) | 37 (5.7) | .005 |
| Cirrhosis | 50 (1.6) | 20 (3.1) | .02 |
| Dementia | 372 (12.2) | 36 (5.5) | <.001 |
| Enteral tube feeding | 36 (1.2) | 16 (2.5) | .01 |
| Chronic renal failure | 315 (10.3) | 85 (13.0) | .04 |
| Hemodialysis | 34 (1.1) | 18 (2.8) | .001 |
| ICS use | 462 (15.2) | 128 (19.6) | .005 |
| PPI use | 777 (25.5) | 251 (38.5) | <.001 |
| Indwelling catheter | 52 (1.7) | 27 (4.1) | <.001 |
| Prior mycobacteria diseases | 70 (2.3) | 26 (4.0) | .01 |
| Prior ESBL | 39 (1.3) | 16 (2.5) | .02 |
| Prior Pseudomonas | 68 (2.2) | 33 (5.1) | <.001 |
| Severe CAP | 840 (27.5) | 190 (29.1) | .41 |
Abbreviations: CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; ESBL, extended-spectrum β-lactamase; ICS, inhaled corticosteroids; IQR, interquartile range; PPI, proton pump inhibitors.
aData represent No. (%) unless otherwise specified.